Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics director Edward Kaye resigns; Bo Cumbo appointed to board

Neutral Impact 2 of 5 leadership Written later

Stoke Therapeutics disclosed that Director Edward M. Kaye, M.D. resigned from the Board and its Research and Development Committee effective September 23, 2026, and that the company said the resignation was not due to any disagreement. The Board appointed Alexander (Bo) Cumbo as a Class III director the same day to fill the vacancy, a board change that is routine for shareholders.

Key points

  • Edward M. Kaye, M.D. resigned as Class III director and from the R&D Committee, effective September 23, 2026; the filing says no disagreement was involved.
  • Alexander (Bo) Cumbo appointed Class III director effective September 23, 2026, with a term expiring at the 2028 Annual Meeting.
  • Cumbo receives a $45,000 annual cash retainer and an initial stock option for 39,674 shares, valued at approximately $724,000 under ASC 718.
  • The Board determined Cumbo is independent under SEC and Nasdaq rules.

The filing

CompanyStoke Therapeutics, Inc. (STOK)
Form8-K, current report
Filed with the SECSep 25, 2026, 4:05 PM ET
Accession number0001193125-26-402820

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.